News Releases

Apr 09, 2020
Sangamo Announces Closing of Biogen Collaboration Agreement
- Sangamo has received $225 million in stock proceeds; will receive additional $125 million upfront license fee by May 8, 2020 BRISBANE, Calif. --(BUSINESS WIRE)--Apr. 9, 2020-- Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced the closing of its previously
Additional Formats
PDF Version
Feb 27, 2020
Biogen and Sangamo Announce Global Collaboration to Develop Gene Regulation Therapies for Alzheimer’s, Parkinson’s, Neuromuscular, and Other Neurological Diseases
Broad collaboration for gene regulation therapies in neurology, initially focused on development of ST-501 for tauopathies including Alzheimer’s disease, ST-502 for synucleinopathies including Parkinson’s disease, and a neuromuscular target, with exclusive rights for nine additional undisclosed
Additional Formats
PDF Version
Feb 12, 2020
Sangamo Therapeutics Appoints John Markels to Its Board of Directors
BRISBANE, Calif. --(BUSINESS WIRE)--Feb. 12, 2020-- Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced the appointment of Dr. John Markels , an accomplished pharmaceutical executive with three decades of general management, manufacturing and technology experience
Additional Formats
PDF Version
Displaying 11 - 20 of 21